

Index

A

- Acridanes, antipsychotics, 34
- Acute mania. *See* Mania, short-term treatment
- Agranulocytosis, clozapine risk, 75–76
- Akathisia, 68
- Alzheimer's dementia, 252
- American Psychiatric Association, 6, 57, 66, 90, 111, 155
- Anticonvulsants
 - actions
 - FDA approval, 102
 - L-glutamate, 105
 - MARKS enzyme, 104
 - molecular action and target, 103, 104
 - PKC, 104
 - potential target, 104
 - adverse effects
 - drug-drug interactions, 131–132
 - hepatic toxicity, 131
 - polycystic ovaries with the syndrome, 132
 - rashes, 131
 - carbamazepine, 98–100
 - gabapentin, 102
 - lamotrigine, 101–102
 - metabolism, 99
 - mood-stabilizing agents, 93
 - oxcarbazepine, 102
 - topiramate, 102
 - valproic acid, 100–101
- Antidepressants
 - fluoxetine, 156
 - imipramine, 158
 - indalpine, 159
 - iproniazid, 157–158
 - MAO inhibitors 161–162, 165
 - serotonin-reuptake inhibitors (SRIs), 160–163
 - serotonin-norepinephrine reuptake inhibitors (SNRIs), 161, 164
 - zimelidine, 159
 - actions
 - cerebral monoamine systems, 167–170
 - monoamine neurotransmission, 158, 164–167
 - noradrenergic and serotonergic nerve terminals, 170–173
 - pharmacodynamics, 173–176
 - scheme of, 176–179
 - adverse effects
 - autonomic effects, 211–212
 - cardiac risks, 212–213
 - drug interactions, 215–218
 - overdoses lethality, 218–220
 - in pregnancy, 220–221
 - withdrawal reactions, 213–215
 - clinical treatment
 - age vs. response, 196–197
 - behavioral supplementation, 200
 - broadening applications, 205–206
 - clinical effects, 210–211
 - costs, 205–206
 - diagnosis of depression, 198–199
 - discontinuation risks, 201–202
 - dosing and time course, 182–185
 - compared to ECT, 196
 - efficacy, 192, 194
 - long-term maintenance treatment and discontinuation, 200–205

- meta-analytic pooling, 189, 202–203
- methodological considerations, efficacy, 190–192
- optimization, placebo contrasts, 192–196
- pregnancy, 219–221
- psychosis present, 194–196
- recent findings, efficacy, 192
- selection, comparative efficacy, 185–190
- and suicidal risk, 206–211
- treatment-resistant depression management, 196–199
- trial design, 203–204
- discovery of, 157–159
- disposition
 - in children, 181
 - CYP450, 179
 - pharmacokinetics, 180
 - plasma concentration, 181
- doses, 183
- vs. fluoxetine, 186
- lithium augmentation, 199
- Montgomery-Åsberg Depression Rating Scale (MADRS), 190
- vs. placebo in controlled trials, 189
- types
 - historical evolution, 159, 160
 - monoamine oxidase inhibitors, 161
 - natural products, 163
 - serotonin-norepinephrine-reuptake inhibitors, 164
 - serotonin-reuptake inhibitors, 160, 163
 - tricyclic agents, 162
- Antipsychotic–antimanic drugs, 105–106
- Antipsychotic malignant syndrome (AMS), 71–72
- Antipsychotics
 - actions, 48
 - adverse effects
 - akathisia, 68, 70
 - cardiac risks and sudden-death, 73–74
 - clozapine risk, 75–76
 - dose-dependency, 59
 - dystonia, 70
 - Extrapyramidal syndromes (EPS), 33, 51
 - hyperprolactinemia, 75
 - malignant syndrome, 71–72
 - metabolic abnormalities, 76–77
 - neurological effects, 68–73 (*see also* Neurological effects, antipsychotics)
 - weight-gain and metabolic syndrome, 67
- agents
 - characteristics, 36
 - chlorpromazine, 32
 - clozapine, 33
 - first-generation, 33
 - modern, 31–33
 - Rauwolfia serpentina*, 31
 - reserpine, 32
 - second-generation, 33–34, 38
 - tetrabenazapine, 31, 32
- clinical use
 - antipsychotic preparations, long-acting, 61–62
 - comparative efficacy, drugs, 62–65
 - continued vs. discontinued treatment, 58
 - costs, 62–65
 - data pooling, 63
 - diagnostic assessment, 63
 - discontinuation, 57–59
 - dose-response, 61–62
 - drug-discontinuation trials, 57–59
 - drug monitoring, 49–50
 - drugs vs. placebo, efficacy, 65
 - efficacy vs. placebo, 64–65
 - equivalent doses, 37–38
 - evidence-based medicine, 62
 - expected effects and selection, 50–52
 - formulations, 49
 - long-term dosing, 59–61
 - long-term treatment, 56–57
 - meta-analyses, 62–63
 - monitoring, 49–50
 - psychotic-disorder patients, long-term care, 65–67
 - selection, 50–52
 - shorter hospitalization impact, 54–55
 - short-term dosing, 54
 - short-term indications, 52–53

- tolerance, 59
 - treatment, time-course, 53
 - continued vs. discontinued treatment, 58–59
 - pharmacology
 - acridanes, 34
 - bottleneck enzymatic step, 45, 47
 - butyrophenones, 35
 - catecholamines metabolism, 40
 - characteristics, 36
 - depot preparations, 39
 - dibenzepines, 34–35
 - dopamine receptors function, 40–48
 - droperidol, 37
 - drug interactions, 40–41
 - equivalent doses, 39
 - exocytosis, 47
 - fentanyl, 37
 - fluspiriline, 37
 - G proteins, 41
 - haloperidol, 35
 - long-acting injected
 - antipsychotic agents, 40
 - meperidine, 35
 - norepinephrine interactions, 44
 - penfluridol, 37
 - phenothiazines, 34
 - pimozide, 37
 - potencies, central
 - neurotransmitter receptors, 42
 - pro-drugs, 39
 - thioxanthenes, 34
 - tricyclic compounds, 34–35
 - treatment, current status, 77
 - Arachidonic acid (AA), 104
 - Aripiprazole
 - antidepressant supplementation, 199
 - bipolar disorder, 105
 - dose, 39
 - long-term indications, 56
 - low-EPS-risk, 73
 - structure, 38
 - Arrhythmias, antipsychotics effects, 73–74
 - Asenapine, 34, 37, 38
 - Autonomic effects, antidepressants, 211–212
- B**
- Biological hypotheses, psychiatry
 - depressed and elevated mood, 22
 - pathophysiological factors, 23
 - pharmacocentric theories, 22–24
 - phenotype problem, 24
 - psychotoxins, 22
 - Bipolar disorder treatment, 91
 - antisuicidal effects, 125–127
 - bipolar II disorder, 109–100
 - bipolar depression and mixed states, short-term treatment
 - antidepressants usage, 109–110
 - lamotrigine efficacy, 110
 - meta-analyses, 111
 - physical methods, 111
 - regulatory approval, 112
 - discontinuation of
 - lithium, 122
 - in pregnancy, 123, 124
 - recurrence, 121
 - relapses risk, 122
 - treatment-discontinuation protocol, 123
 - withdrawal reactions, 121
 - in women, 123, 124
 - indication approval status, 105
 - long-term treatment
 - adherence to, 120–121
 - clinical trials, 116–117
 - combination treatment, 114
 - meta-analysis, lithium treatment, 115
 - methodological perspective, 118
 - mood stabilizers, 117, 118
 - prophylactic initiation, 112–114, 117
 - residual morbidity, 118, 119
 - statistical method, 118
 - mania, short-term treatment
 - clinical trials, 108–109
 - indication, 106
 - lithium salt effect, 106
 - meta-analysis, 106
 - research findings, 108
 - response rate, 108
 - Body-mass-index (BMI), 67
 - Brief Psychiatric Rating Scale (BPRS), 55
 - Butyrophenones, antipsychotics, 35

C

Carbamazepine, 98–100
 Cardiac risks
 antidepressants adverse effects, 212–213
 antipsychotics effects, 73–74
 Catecholamine metabolism, 40, 167–173
 Cerebral monoamine systems, 167–170

Chlorpromazine

 as antimanic agent, 31
 bipolar disorder, indications, 105
 characteristics, 36
 clinical experience, 33
 dose-response, 60–61
 equivalent doses, 39
 formulations, 49
 history of, 32–33
 preanesthetic sedative, 32
 structure, 35
 utilization, 3

Clozapine

 antipsychotics agents, 33
 antipsychotic treatment, current status, 77
 cardiac abnormalities, 74
 characteristics, 7, 36
 drug interactions, 215–216
 drug monitoring, 50
 equivalent doses, 39
 long-term antipsychotic dosing, 59
 potencies, 42
 risks, 75–76
 schizophrenia
 rehospitalization risk, 66
 suicidal risk, 208
 serendipity, 8
 structure, 38
 tricyclic dibenzodiazepine compound, 33

D

Decanoates, 49
 Diagnostic and Statistical Manual (DSM), 6, 90, 253
 Dibenzepines, antipsychotics, 34–35
 Discontinuation, treatment, 121. *See also* Withdrawal symptoms
 Divalproex
 anticonvulsants (*see* Valproic acid)
 mood-stabilizing agents, 92
 Dopamine receptors, antipsychotics

 cerebral dopaminergic synapse, 44, 46
 dopaminergic neurotransmission, 43
 drug interactions, 40–41
 exocytosis, 47
 function, 40–43
 IP₃, 48
 molecular neurobiology, 43
 norepinephrine interactions, 44
 presynaptic apparatus, 45
 release of, 47
 systems, mammalian brain, 44–45
 tyrosine, 45
 visualization, 43
 Droperidol, 37
 Dystonias, 68, 70

E

Electroconvulsive treatment (ECT), 65, 126, 195
Ephedra sinica, 157
 European Medicines Agency (EMA), 12
 Exocytosis, 47
 Extrapyramidal syndromes (EPS), 33, 37

F

Fentanyl, antipsychotics, 37
 Fetal valproate syndrome, 134
 Floppy-baby syndrome, 134
 Fluphenazine, 35, 40, 61
 Fluspiriline, antipsychotics, 37
 Fluvoxamine, 159

G

Gabapentin, anticonvulsants, 102
Ginko biloba, 73
 G proteins, antipsychotics, 41

H

Hamilton Depression Rating Scale (HDRS), 190
 Haloperidol
 antipsychotics, 35
 butyrophenones, 35
 equivalent dose, 39
 history, 10
 long-acting, injected antipsychotic preparations, 61

- long-term antipsychotic dosing, 59
- meta-analysis, 107
- radioactively-labeled, 41
- structure, 37

Hospitalization impact, antipsychotics, 54–55

Hypericum, 163

Hyperprolactinemia, antipsychotics effects, 75

Hypertension

- antidepressant-antianxiety agents, 212
- Rauwolfia alkaloids, 31
- venlafaxine overdoses, 219

Hysteroid dysphoria, 190

I

Iloperidone, 38, 67

Imipramine, 158

Indalpine, 159

International Classification of Diseases (ICD), 6, 90, 253

Iproniazid, 157

L

Lamotrigine

- anticonvulsants, 101–102
- mood-stabilizing agents, 92

Leukopenia, clozapine risk, 76

Lithium salts

- actions, pharmacodynamic
 - cerebral effects, 95
 - interferes with, 94, 95
 - PKC inhibition, 95
- adverse effects
 - acne, 129
 - alopecia, 129
 - dermatological disorders, 129
 - drug-drug interactions, 130
 - drug effects, serum
 - concentrations, 130
 - hypothyroidism/myxedema, 130
 - intoxication, 127
 - psoriasis, 129
 - slow-release preparation, 129
 - weight-gain, 129
- carbonate
 - as antimanic agent, 31, 94, 106
 - gout treatment, 92
 - mood-stabilizing agent, 91

- slow-release preparations, 97
- development, 92, 94
- discontinuation, bipolar disorder treatment, 122
- dosing and monitoring, in treatment
 - dose-response relationship, 96–97
 - generic tablets/capsules, 95
 - limitation, 96
 - serum samples, assays of, 96
 - slow-release preparations, 97–98
 - therapeutic index, 96
- elimination, 98
- exposure, pregnancy, 134
- treatment for, 94

Loxapine, antipsychotic agent, 37

Lurasidone, antipsychotic agent, 38

M

Mania, short-term treatment

- clinical trials, 108–109
- indication, 106
- lithium salt effect, 106
- meta-analysis, 106
- research findings, 108
- response rate, 108

Manic-depressive disorder. *See* Bipolar disorder

Maternal mental health, 123–124

Medicines and Healthcare products Regulatory Agency (MHRA), 12

Meperidine, antipsychotics, 35

Metabolic syndrome

- antipsychotics, side effects, 67
- older antidepressants, 212

Molindone, 35, 37, 49

Monoamine neurotransmission, 164–167

Monoamine oxidase inhibitors (MOI), 161

Montgomery-Asberg Depression Rating Scale (MADRS), 190

Mood-stabilizing agents

- adverse effects
 - anticonvulsant mood stabilizers, 131–132
 - discontinuation, 123, 131–132
 - lithium, 127–130
 - pregnancy, 132–135
- anticonvulsants
 - actions, 102–105

- carbamazepine, 98–100
 - gabapentin, 102
 - lamotrigine, 101–102
 - oxcarbazepine, 102
 - topiramate, 102
 - valproic acid, 100–101
 - antipsychotic–antimanic drugs, 105–106
 - efficacy, 134
 - bipolar disorder treatment
 - antisuicidal effects, 125–127
 - bipolar depression and mixed states, short-term treatment, 109–112
 - long-term prophylactic treatment initiation, 112–114
 - long-term treatment, 114–121
 - mania, short-term treatment, 106–109
 - treatment discontinuation, 121–125
 - definition, 91
 - FDA-approved agents, properties, 93
 - history, 89–91
 - lithium salts
 - actions, 94–95
 - carbonate, 91
 - development, 92, 94
 - dosing and monitoring, in treatment, 95–98
 - elimination, 98
 - treatment for, 94
 - unipolar depression, 90
 - long-term treatment, 112–120
 - short-term treatment, 106–109
 - Mood-stabilizing anticonvulsants. *See* Anticonvulsants
- N**
- National Institute for Health and Clinical Excellents (NICE), 12
 - Neurological effects, antipsychotics
 - akathisia, 68
 - antipsychotic malignant syndrome, 71–72
 - characteristics, 69
 - dystonias, 68, 70
 - extrapyramidal syndromes, 68
 - malignant syndrome, 218
 - Parkinsonism, 70–71
 - rabbit syndrome, 71
 - tardive (late) dyskinesias, 72–73
 - Noradrenergic and serotonergic nerve terminals, 170–173
- O**
- Olanzapine, 34, 38
 - Overdoses lethality, antidepressants, 218–220
- P**
- Paliperidone, 38, 40
 - Pamoate complex, 49
 - Parkinsonian bradykinesia, antipsychotics actions, 48
 - Parkinsonism, 70–71
 - Parkinson's disease, 252
 - Parkinson's law, 55
 - Penfluridol, antipsychotics, 37
 - Phenergan[®]. *See* Promethazine
 - Phenothiazines
 - as antimanic agent, 31
 - antipsychotics, 34
 - doses, 39
 - first-generation agents, 33
 - history of, 10, 31
 - lethality, overdose, 219
 - perinatal risks, 133
 - structure, 35
 - Phenyltriaazines, anticonvulsant. *See* Lamotrigine
 - Pimozide, antipsychotics, 37
 - Polycystic ovaries with the syndrome, anticonvulsants adverse effects, 132
 - Polytherapy, antipsychotics, 51
 - Pregnancy
 - antidepressants adverse effects, 220–221
 - bipolar disorder treatment discontinuation, 123, 124
 - mood-stabilizing agents adverse effects
 - blood-brain diffusion, 132
 - fetal structural anomalies, 132
 - lithium exposure, 134
 - perinatal risks, 122–13, 133
 - valporate exposure, 134
 - Promethazine, 32
 - Psychoneuroses, 155
 - Psychopharmacology. *See also* Psychotropic drugs

- Alzheimer's dementia/Parkinson's disease, 252
 - clinical care improvement
 - costs, 259, 260
 - critical challenge, 258
 - lapses, 257
 - medication-adherence
 - improvement, 258
 - treatment effectiveness,
 - limitation, 256, 257
 - compartmentalization, 253
 - drug-associated changes
 - allopathic compulsion, 256
 - current status, 254
 - efficiency and cost-containment, 253–254
 - limitations and risk, 255
 - pharmacocentric approach, 255–256
 - polytherapy, 256
 - drug discovery, 252
 - functional assessments, 261
 - historical evolution, 10
 - managed serendipity, 252–253
 - methodological concepts, 16, 17
 - modern era of, 1–2
 - pathophysiology and etiology, 252
 - psychiatric chemotherapy, 251
 - psychiatric nosology, 253
 - Psychotic disorders prevalence, 89
 - Psychotropic drugs
 - clinical management, 4
 - clinical trials
 - blinding, 15
 - carryover and withdrawal artifacts, 19–20
 - clinical heterogeneity, 15
 - design and analysis, 16, 17
 - drug dosing, 19
 - drug–placebo contrasts, 18
 - long-term/prophylactic trials, 20–21
 - pivotal trials, 16, 18
 - randomization, 15–16
 - reporting and pooling, data, 21–22
 - subject recruitment, 14–15
 - survival analysis, 16
 - trial size effects, 13–14
 - development phases
 - evidence-based therapeutics, 13
 - human experimentation, 10–11
 - license approval, 12
 - Phase I, 10–11
 - Phase II, 11
 - Phase III, 11–12
 - Phase IV, 12
 - preclinical steps, 8–9
 - regulatory agencies, 12
 - diagnosis and classification, 5–6
 - discovery
 - characteristics, in development, 7
 - cost, 7
 - effects and limitations of, 7
 - historical evolution, 10
 - from natural products, 6
 - new-drug development & approval, 8, 9
 - serendipitous observation, 8
 - generic brand names, 2, 4
 - institutional trends and hospitalization, USA, 5
 - needs and markets, 2
 - neurological disorder prevalence, 1, 3
- Q**
- Quetiapine, 34, 38, 71, 110
- R**
- Rabbit syndrome, 71
 - Rauwolfia serpentina*, 31
 - Reserpine
 - antiadrenergic effects, 1
 - characteristics, 7
 - isolation of, 31
 - serendipity, 8
 - structure, 32
 - Restlessness and agitation, 212
 - Risperidone
 - antipsychotics formulations, 49
 - carbohydrate microspheres, 39
 - characteristics, 36
 - depot, 40
 - hyperprolactinemia treatment, 75
 - long-term antipsychotic dosing, 59
 - schizophrenia patients, 66
 - structure, 37, 38

S

- Schizophrenia
 - antidepressants, 195
 - antipsychotics
 - continued vs. discontinued treatment, 58
 - dose-response, 61
 - expected effects and selection, 50
 - long-term treatment, 56
 - short-term indications, 52
 - chlorpromazine, 33
 - clozapine risk, 75
 - long-term treatment, 56–57
 - rehospitalization risk, 66
 - suicidal risk, 208
- Serotonin-reuptake inhibitors (SRIs), 160, 163
- Snakeroot, as antipsychotics. *See* *Rauwolfia serpentina*
- Standardized mortality ratio (SMR), 207–208
- Stevens-Johnson syndrome, 100, 131
- Suicidal risk and antidepressants
 - adverse response, 211
 - A/S ratio, 208
 - causes, 206, 208
 - FDA reported outcomes, 209
 - odds ratio, 210

T

- Tardive (late) dyskinesias (TD), 72–73
- Tetrabenazapine, 31–32, 73
- Thioridazine, 4, 33–36, 39, 42, 73, 212
- Thiothixene, 4, 33–36, 39
- Thioxanthenes, antipsychotics, 7, 34
- Thorazine ®. *See* Chlorpromazine

- Topiramate, anticonvulsants, 102
- Tourette syndrome, pimozide, 37
- Tricyclic neuroleptic-antipsychotic agents, 34–35
- Tyrosine, dopamine receptors, 45

U

- Unipolar depression, mood-stabilizing agents, 90

V

- Valproic acid & salts, anticonvulsants, 100–101

W

- Weight gain
 - antidepressants, 212
 - antipsychotics, side effects, 67
 - mood-stabilizing agents, 129
- Withdrawal symptoms
 - clinical trials, psychotropic drugs, 19–20
 - discontinuation effects
 - antidepressants, 213–214
 - antipsychotics, 59
 - bipolar disorder, 121–123
 - experimental therapeutic trials, 19–20
 - negative symptoms, 53
- World Health Organization (WHO), 155

Z

- Zimelidine, 159
- Ziprasidone, 4, 35–39, 68, 74, 105, 107, 174